-
-
- Cat. No.
- A13530
Flumatinib mesylate
Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
In stock View Details -
- Cat. No.
- A13562
NRC-AN-019
Synonyms: AN019
NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells.
In stock View Details -
- Cat. No.
- A15003
AST 487
Synonyms: NVP-AST 487
AST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
In stock View Details -
- Cat. No.
- A15849
Olverembatinib Dimesylate (GZD824)
Synonyms: GZD-824 Dimesylate; GZD824
GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
In stock View Details -
- Cat. No.
- A15887
GNF-7
GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of
In stock View Details -
- Cat. No.
- A16258
Flumatinib
Synonyms: HHGV678
Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively.
In stock View Details -
- Cat. No.
- A16264
Olverembatinib (GZD824)
Synonyms: GZD 824
GZD824 is a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I.
In stock View Details -
- Cat. No.
- A16265
Lyn-IN-1
Synonyms: INNO406; NS187; Bafetinib
Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.
In stock View Details -
- Cat. No.
- A16266
ON 146040
ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways; inhibits PI3K α/δ isoforms with IC50 of 14/20 nM.
In stock View Details -
- Cat. No.
- A17553
Nilotinib hydrochloride
Synonyms: AMN107 hydrochloride
Nilotinib hydrochloride is a potent Bcr-Abl tyrosine kinase inhibitor that exhibits significant antineoplastic activity. It is primarily utilized in research related to chronic myelogenous leukemia (CML), providing valuable insights into the molecular mechanisms of this disease and potential therapeutic strategies. Its oral bioavailability makes it a convenient choice for in vitro and in vivo studies focused on targeting the Bcr-Abl fusion protein.
In stock View Details -
- Cat. No.
- A18567
SNIPER(ABL)-062
SNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the BCR-ABL protein.
In stock View Details -
- Cat. No.
- A19079
CHMFL-ABL-121
CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.
In stock View Details -
- Cat. No.
- A19444
CZC-8004
Synonyms: CZC-00008004
CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase.
In stock View Details -
- Cat. No.
- A19488
AZD0424
AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells.
In stock View Details -
- Cat. No.
- A19607
SNIPER(ABL)-024
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5μM.
In stock View Details -
- Cat. No.
- A19658
Asciminib
Synonyms: ABL001
Asciminib (ABL001) is a potent and selective allosteric Bcr-Abl inhibitor; inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
In stock View Details -
- Cat. No.
- A19742
CT-721
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.
In stock View Details -
- Cat. No.
- A21043
BCR-ABL-IN-2
BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively.
In stock View Details -
- Cat. No.
- A21790
1-Naphthyl PP1 hydrochloride
Synonyms: 1-NA-PP 1 hydrochloride
1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).
In stock View Details -
- Cat. No.
- A22279
GMB475
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance.
In stock View Details -
- Cat. No.
- A22504
Vodobatinib
Synonyms: K-0706
Vodobatinib, also known as K-0706, is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
In stock View Details -
- Cat. No.
- A22645
Multi-kinase inhibitor 1
Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl.
In stock View Details -
- Cat. No.
- A23950
SIAIS100 TFA
SIAIS100 TFA is a potent PROTAC degrader targeting BCR-ABL, with a DC₅₀ of 2.7 nM. It is a valuable tool for studying BCR-ABL signaling and therapeutic strategies in chronic myeloid leukemia (CML).
In stock View Details -
- Cat. No.
- A24098
SB1-G-187
SB1-G-187 is a multifunctional PROTAC designed as a multi-kinase degrader, capable of inducing the selective degradation of multiple kinase targets through the ubiquitin–proteasome system. In addition to its targeted degradation activity, SB1-G-187 features an alkyne functional group, enabling its use as a click chemistry reagent. It can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules, allowing for versatile applications in chemical biology, such as probe development, conjugation, and target identification.
In stock View Details